{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ESCC&page=2", "query": { "condition": "ESCC", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ESCC&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ESCC&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T15:34:02.838Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07189871", "title": "177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Cancer (CRPC)", "Colorectal Cancer", "NSCLC (Non-small Cell Lung Cancer)", "Ovarian Cancer", "Cervical Cancer", "Endometrial Cancer", "TNBC, Triple Negative Breast Cancer", "Small Cell Lung Cancer (SCLC )", "Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)", "Esophageal Squamous Cell Carcinoma (ESCC)", "Sarcoma" ], "interventions": [ { "name": "177Lu-BetaBart", "type": "DRUG" }, { "name": "BetaBart + unlabeled BetaBart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Radiopharm Theranostics, Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2026-02-23", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-22T15:34:02.838Z", "location_count": 5, "location_summary": "Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska + 1 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07189871" }, { "nct_id": "NCT04641871", "title": "Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumor" ], "interventions": [ { "name": "Sym021", "type": "DRUG" }, { "name": "Sym022", "type": "DRUG" }, { "name": "Sym023", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2020-10-12", "completion_date": "2024-06-03", "has_results": false, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-22T15:34:02.838Z", "location_count": 12, "location_summary": "Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04641871" }, { "nct_id": "NCT07503808", "title": "A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Squamous Cell Carcinoma", "High Grade Serous Ovarian Cancer", "Head and Neck Squamous Cell Carcinoma", "Colorectal Cancer", "Castration-resistant Prostate Cancer", "Non Small Cell Lung Cancer", "Endometrium Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "IDE034", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDEAYA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2026-02-24", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-22T15:34:02.838Z", "location_count": 15, "location_summary": "Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 10 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07503808" }, { "nct_id": "NCT05462873", "title": "A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Renal Cell", "Esophageal Squamous Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "QEQ278", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 30, "start_date": "2023-04-04", "completion_date": "2026-01-26", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-10-22T15:34:02.838Z", "location_count": 4, "location_summary": "Los Angeles, California • Fort Myers, Florida • Boston, Massachusetts", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462873" }, { "nct_id": "NCT07224750", "title": "A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatocellular Carcinoma (HCC)", "Cholangiocarcinoma", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Esophageal Squamous Cell Carcinoma (ESCC)", "Gastric Cancer (GC)", "Colorectal Cancer Screening" ], "interventions": [], "intervention_types": [], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2024-06-21", "completion_date": "2028-06-18", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-22T15:34:02.838Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224750" }, { "nct_id": "NCT03430843", "title": "A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Squamous Cell Carcinoma (ESCC)" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 512, "start_date": "2018-01-26", "completion_date": "2022-12-28", "has_results": true, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-10-22T15:34:02.838Z", "location_count": 2, "location_summary": "Detroit, Michigan • Toledo, Ohio", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03430843" }, { "nct_id": "NCT04210115", "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Squamous Cell Carcinoma (ESCC)", "Gastroesophageal Junction Carcinoma (GEJC)", "Esophageal Adenocarcinoma (EAC)" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "radiotherapy", "type": "RADIATION" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "levoleucovorin", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 703, "start_date": "2020-02-28", "completion_date": "2026-06-23", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-22T15:34:02.838Z", "location_count": 19, "location_summary": "Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04210115" }, { "nct_id": "NCT05945823", "title": "Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Cancer", "Siewert Type 1 GEJ Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Futibatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2023-07-13", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-22T15:34:02.838Z", "location_count": 16, "location_summary": "Santa Monica, California • Denver, Colorado • Miami Beach, Florida + 13 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05945823" }, { "nct_id": "NCT06644781", "title": "A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Ifinatamab deruxtecan", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan hydrochloride (HCl)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 510, "start_date": "2025-03-27", "completion_date": "2029-11-01", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-22T15:34:02.838Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Fullerton, California • Orange, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06644781" }, { "nct_id": "NCT03518554", "title": "A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Head and Neck Cancer", "Esophageal Cancer", "Other Metastatic Solid Tumors" ], "interventions": [ { "name": "JAB-3068", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacobio Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2018-04-23", "completion_date": "2022-02-03", "has_results": false, "last_update_posted_date": "2024-12-16", "last_synced_at": "2026-10-22T15:34:02.838Z", "location_count": 4, "location_summary": "Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03518554" } ] }